amylin. Amylin is released by the same pancreatic beta cells that release insulin, and acts in concert with insulin in response to elevated blood glucose to optimize energy balance by reducing food intake, slowing gastric emptying and suppressing secretion of glucagon after a meal. 2, 3 These coordinated actions seem to be mediated by actions in the brain, beginning with the area postrema, 3, 4 and then to the forebrain and lateral hypothalamus. 3 Similar to many other centrally active hormones, 5 injection of amylin into the brain results in reduced food intake and body weight, independent of the body weight at the start of treatment. Also, similar to the melanocortin peptides, 5 acute administration of the amylin agonist, salmon calcitonin, centrally results in reduced energy expenditure. Interestingly, animals overfed for 3 weeks with an energy-dense diet were resistant to amylin's effect on body weight. Thus, although amylin receptors might serve as useful targets in the battle against overweight, there might be limitations to their regulatory actions precisely in the populations that are the target for the potential therapeutic use of amylin, which is not dissimilar to the results of even moderate fat diets in obesity-prone rats suppressing responses to anorexigenic hormones like leptin or melanocortins. 6 Despite this, the numerous physiological regulators of meal size and energy expenditure, such as amylin, that have emerged over the past few years certainly provide an array of therapeutic targets for the treatment of obesity. However, the most effective intervention for obesity is bariatric surgery. Surprisingly enough, in many cases, the surgery is not just a mechanical intervention, but also results in a profound change in endocrine profiles. Two papers report different aspects of the remarkable and unexpected changes brought about by the different forms of surgical intervention for obesity and diabetes.
The paper by Tadross and le Roux, details the prolonged and profound effect that bariatric surgery can have on body weight. 7 Two procedures are discussed, the Roux-en-Y gastric bypass (RYGB) and the laparoscopic adjustable gastric banding (LAGB). Both procedures result in significant (initially 20-40%) and sustained weight loss in bariatric patients, a strongly decreased long-term mortality, and improvements in comorbidities such as cardiovascular parameters, fatty liver disease, sleep apnea, and even psychological and economic profiles, to list just a few. [8] [9] [10] The most remarkable improvement is the nearly immediate resolution of type 2 diabetes (T2DM) in the great majority of diabetic patients undergoing RYGB. To understand this last beneficial effect of surgery, the endocrine profiles of the RYGB patients have been examined carefully. The procedure results in the food bypassing 95% of the stomach, and much of the small intestine, including all of the duodenum. LAPD, which restricts the size of the stomach through an adjustable band, does not re-route the gastrointestinal (GI) tract. The results of these procedures are not considered to be explained primarily by malabsorption, or restriction, but are instead considered to arise from changes in the enteroendocrine profile of the patient. [11] [12] [13] Levels of the orexigenic hormone ghrelin were reduced in RYGB patients in some, but not all, studies; responses to the anorexigenic hormones peptide-YY (PYY) and glucagon-like peptide 1 (GLP-1) were elevated and the patients' sense of taste might even have been changed. Although the jury is still out on the mechanisms resulting in the dramatic and sustained weight loss associated with the bariatric surgeries, it is clear that understanding the mechanisms of this will remain a ripe area of research for some time. The paper by Cummings, 14 focuses largely on the nearly miraculous and instant relief of the T2DM that occurs with some bariatric surgical interventions. The change from strong dependence on medications for control of blood glucose to complete euglycemia without any medication can occur within the duration of the postoperative hospital stay of about 3 days. Ultimately, over 80% of the patients with RYGB undergo complete remission of the T2DM. 9 Many of the benefits associated with normoglycemia, such as a remarkable decrease in diabetes-related deaths, were observed. The mechanism underlying this remarkable change in disease course with RYGB surgery has been the subject of intense debate. The primary cause is unlikely to be weight loss. First, although there is a significant weight loss associated with the surgery, the euglycemia occurs well before this happens. 15 Several studies matching weight loss and glycemic control suggest that the mechanism by which the RYGB or another malabsorptive surgery, biliopancreatic diversion (BPD), permits euglycemia is not primarily due to weight loss, especially when compared with equivalent, but merely restrictive surgical procedures such as adjustable gastric banding (AGB). 16 Various hypotheses have been tested in experimental animals and humans. One hypothesis, which has supporting evidence in animals and humans, is that bypassing the proximal small intestine might reduce the levels of the orexigenic hormone, ghrelin. Another hypothesis, which has evidence in its favor, is that the expedited delivery of nutrients to the lower intestine enhances secretion of GLP-1, an incretin that enhances glucose tolerance by increasing insulin secretion and other mechanisms. Finally, there is evidence that preventing the upper small intestine from coming in contact with nutrients has antidiabetic effects. On the basis of these presentations at the Merck Frosst/ CIHR Research Chair in Obesity Symposium, it can be inferred that there is a very diverse set of approaches to understanding the causes and treatment of obesity and diabetes being pursued with lively interest in the laboratories and clinics of many countries. This provides me with the basis for confidence that a solution to treatment will emerge, in parallel with a deeper understanding of the complexities in the systems regulating body weight and glucose homeostasis.
Conflict of interest
The author has declared no financial interests.
